S100A9 and acute myeloid leukemia: Using western blot analysis, we validated the effect on downstream targets and could observe a significant reduction in c-MYC and BCL-2 expression using S100A9-siRNA combined with venetoclax compared to single agent treatment of both AML cell lines (Fig. 5D, E, Supplemental Fig. 11).